Drugs / aIIV4c
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04576702 | Oct 2020 → Mar 2021 | influenza | Seqirus | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | aIIV4c | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04576702 ↗ |
| Known as | aQIVc | “By adding an adjuvant and using cell-based vaccine production methods, the MF59-adjuvanted quadrivalent cell-based influenza vaccine (aQIVc) may boost immunogenicity and...” PMID 39946829 ↗ Feb 2025 |
| Modality | Vaccine | “Investigational MF59 Adjuvanted Cell-derived Quadrivalent Influenza vaccine” NCT04576702 ↗ |
| Route | Intramuscular | “aIIV4c will be administered as a single dose intramuscularly on Day 1” NCT04576702 ↗ |